COMP <GO>
MIRM vs COGT // ENTERPRISE SCALE & MARKET CAP
Mirum Pharmaceuticals Inc. (NASDAQ) VS. Cogent Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: MIRM 8
— COGT 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MIRM
LAST: $85.74 (+0.87%) • MKT CAP: $5.52B
market-cap
$5.52B
LAST: $29.73 (-4.16%) • MKT CAP: $5.38B
market-cap
$5.38B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRM VS. COGT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRM | COGT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | -35.00% | +31.10 | MIRM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.98% | -4.80% | +5.78 | MIRM | /fcf-yield <GO> |
| Operating Margin | -4.20% | -21.50% | +17.30 | MIRM | /operating-margins <GO> |
| Net Profit Margin | -4.50% | -21.20% | +16.70 | MIRM | /net-margins <GO> |
| Revenue Growth (YoY) | 54.70% | 22.00% | +32.70 | MIRM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.29 | 10.84 | -4.55 | COGT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | MIRM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.4 | 47.2 | +1.20 | MIRM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.05 | -0.06 | COGT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 22.0x | +10.00 | COGT | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $5.52B | $5.38B | $136.5M | MIRM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRM REV | COGT REV | MIRM GROSS % | COGT GROSS % | MIRM FCF | COGT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | $933.4M | — | — | $54.9M | -$266.0M |
| FY 2024 | $336.9M | $772.6M | — | — | $9.3M | -$208.4M |
| FY 2023 | $186.4M | $582.8M | — | — | -$79.3M | -$153.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRM // BETA 0.99
COGT // BETA 1.05